LPL Financial LLC Has $2.32 Million Holdings in Twist Bioscience Co. (NASDAQ:TWST)

LPL Financial LLC cut its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,882 shares of the company's stock after selling 6,462 shares during the period. LPL Financial LLC owned approximately 0.08% of Twist Bioscience worth $2,318,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Thrivent Financial for Lutherans raised its stake in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after acquiring an additional 302,884 shares during the period. American Century Companies Inc. boosted its position in shares of Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after acquiring an additional 293,751 shares in the last quarter. ARK Investment Management LLC raised its position in Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after purchasing an additional 237,772 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Twist Bioscience by 81.9% during the fourth quarter. Principal Financial Group Inc. now owns 374,551 shares of the company's stock worth $17,405,000 after purchasing an additional 168,687 shares during the period.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 1,259 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the transaction, the senior vice president now directly owns 132,014 shares of the company's stock, valued at approximately $6,514,890.90. The trade was a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,796 shares of company stock valued at $1,077,383 in the last 90 days. 3.01% of the stock is owned by insiders.

Twist Bioscience Trading Down 4.3 %

TWST stock traded down $1.65 during midday trading on Friday, reaching $36.80. The company's stock had a trading volume of 747,299 shares, compared to its average volume of 983,176. The business's 50-day simple moving average is $40.57 and its 200-day simple moving average is $44.43. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52 week low of $27.96 and a 52 week high of $60.90. The stock has a market cap of $2.20 billion, a PE ratio of -10.89 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the company earned ($0.75) EPS. The firm's revenue was up 24.1% on a year-over-year basis. As a group, sell-side analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays decreased their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $52.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.